Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1807-1815

  Hwang, Ki Tae ^a   Han, Wonshik ^b   Cho, Jihyoung ^b   Jong, Won Lee ^b   Ko, Eunyoung ^b   Eun, Kyu Kim ^b   Jung, So Youn ^b   Jeong, Eun Mi ^b   Bae, Ji Yeon ^b   Kang, Jason J ^c   Yang, Song Ju ^c   Kim, Sung Won ^b   Noh, Dong Young ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Macrogen Inc   (South Korea)

Author keywords

Array CGH; Breast cancer; Copy number alteration; Predictive marker; Systemic recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; DNA;

ADULT; ARTICLE; ARTIFICIAL CHROMOSOME; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CHROMOSOME 11Q; CHROMOSOME 11Q13.3; CHROMOSOME 11Q24.1; CHROMOSOME 14Q; CHROMOSOME 14Q32.33; CHROMOSOME 15Q; CHROMOSOME 15Q26.3; CHROMOSOME 17Q; CHROMOSOME 17Q25.3; CHROMOSOME 18Q; CHROMOSOME 18Q23; CHROMOSOME 21Q; CHROMOSOME 21Q22.3; CHROMOSOME 5P; CHROMOSOME 5P15.33; CHROMOSOME 9P; CHROMOSOME 9P12; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE MUTATION; GENE NUMBER; GENOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MODEL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; BREAST NEOPLASMS; CLUSTER ANALYSIS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 51949097923     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23672     Document Type: Article

References (48)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thrlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
2. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer. November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
3. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
4. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-25.
5. Davies JJ, Wilson IM, Lam WL. Array CGH technologies and their applications to cancer genomes. Chromosome Res 2005;13:237-48.
6. Taboada EN, Acedillo RR, Luebbert CC, Findlay WA, Nash JH. A new approach for the analysis of bacterial microarray-based comparative genomic hybridization: insights from an empirical study. BMC Genomics 2005;6:78.
7. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res 2006;8:210.
8. Albertson DG. Profiling breast cancer by array CGH. Breast Cancer Res Treat 2003;78:289-98.
9. Cooper CS. Applications of microarray technology in breast cancer research. Breast Cancer Res 2001;3:158-75.
10. Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006;6:92.
11. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 1986;83:2934-8.
12. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
13. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
14. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
15. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-53.
16. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, Zaks TZ, Weber BL High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005;7:R1186-R1198.
17. Ahn SH, Yoo KY. The Korean Breast Cancer Society. Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004. Breast Cancer Res Treat 2006;99:209-14.
18. Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S, Fritz B, Bentz M, Sinn HP, Radlwimmer B, Lichter P. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005;65:439-47.
19. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004;64:8541-9.
20. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 2003;63:8861-8.
21. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995;147:905-11.
22. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, Ellis IO, Porter PL, et al. High-resolution array-CGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007;8:R215.
23. McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD, Schofield AC. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 2005;41:1086-94.
24. Niu Q, Tang ZY, Qin LX, Ma ZC, Zhang LH. Loss of heterozygosity at D14S62 and D14S51 detected by a simple and non-radioactive method in plasma DNA is a potential marker of metastasis and recurrence after curative hepatic resection in hepatocellular carcinoma. Hepatogastroenterology 2003;50:1579-82.
25. Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P. Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res 2001;61:3578-80.
26. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
27. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
28. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
29. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressier L, Nobel A, Parker J, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
30. Perou CM, Srlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
31. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marion MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
32. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marion MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
33. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Srlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43.
34. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
35. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
36. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
37. Janssen EA, Baak JP, Guervos MA, van Diest PJ, Jiwa M, Hermsen MA. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003;201:555-61.
38. Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, Dressman H, Chen CM, Tsai SY, Jian JJ, Liu MC, Nevins JR, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006;24:4594-602.
39. Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol 2007;19:547-51.
40. Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest 2002;82:323-33.
41. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:2883-9.
42. Wang PH, Chen GD, Chang H, Yang SF, Han CP, Lin LY, Ko JL. High expression of human telomerase reverse transcriptase in high-grade intraepithelial neoplasia and carcinoma of uterine cervix and its correlation with human papillomavirus infection. Reprod Sci 2007;14:338-48.
43. Jagadeesh S, Banerjee PP. Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha. Biochem Biophys Res Commun 2006;349:1361-7.
44. Wang YF, Guo KJ, Huang BT, Liu Y, Tang XY, Zhang JJ, Xia Q. Inhibitory effects of antisense phosphorothioate oligodeoxynucleotides on pancreatic cancer cell Bxpc-3 telomerase activity and cell growth in vitro. World J Gastroenterol 2006;12:4004-8.
45. Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T, Miller K, Mller M. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 2005;117:274-80.
46. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. A novel gene. CRR9, which was up-regulated in. CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun 2001;280:1148-54.
47. Selvakumar P, Lakshmikuttyamma A, Lawman Z, Bonham K, Dimmock JR, Sharma RK. Expression of methionine aminopeptidase 2. N-myristoyltransferase, and. N-myristoyltransferase inhibitor protein 71 in HT29. Biochem Biophys Res Commun 2004;322:1012-17.
48. Grne J, Doebler O, Loddenkemper C, Hotz B, Buhr HJ, Bhargava S. Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep 2006;15:1437-43.